Aethlon Medical (AEMD) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
12 Nov, 2026Executive summary
Signed a two-step merger agreement with North Immunology on September 17, 2026; the combined business is expected to operate as North Immunology, with closing expected in Q1 2027 subject to conditions.
The proposed merger would shift the combined business to North Immunology’s pipeline and may wind down legacy Hemopurifier activities; workforce reductions began near quarter-end, with retained staff supporting compliance and the Australian trial.
A proposed contingent value right could provide proceeds from monetizing the legacy Hemopurifier business, but payment is not assured.
Financial highlights
Q2 operating expenses were $2.675M, up 77.2% from $1.510M; net loss was $2.618M versus $1.487M, driven chiefly by merger-related professional fees and no current-period Australian R&D tax incentive.
H1 operating expenses were $4.254M versus $3.302M, and net loss was $4.165M versus $3.249M.
Cash and cash equivalents were $6.487M at September 30, 2026, versus $5.026M at March 31, 2026; H1 operating cash use was $3.633M.
Outlook and guidance
Existing cash resources are expected to fund the reduced operating plan for at least 12 months from financial-statement issuance, including if the merger does not close; the plan includes completing the Australian trial.
If the merger closes, anticipated financing and the combined operating plan are expected to support at least 12 months of operations after closing; closing is expected in Q1 2027, subject to conditions.
Eight patients have been treated across three cohorts; recruitment of one additional patient is intended to conclude in connection with the proposed merger, followed by analysis of available data.
Additional capital would be required to resume or expand Hemopurifier development; roughly $500,000 of ATM capacity remained, subject to market and stock-price conditions.
Latest events from Aethlon Medical
- All proposals except preferred stock authorization were approved, with no stockholder questions.AEMD
AGM 2026 - Shareholders to vote on director elections, capital increases, and future share issuances.AEMD
Proxy filing - Shareholders will vote on major governance, compensation, and capital structure changes at the 2026 meeting.AEMD
Proxy filing - Shareholders are asked to approve major governance, compensation, and capital structure changes.AEMD
Proxy filing - Ongoing oncology trials show Hemopurifier reduces cancer-linked blood markers with strong safety.AEMD
Emerging Growth Conference - Final oncology cohort underway, lower net loss, and $4M financing extend runway 12+ months.AEMD
Q1 2027 - Hemopurifier shows early promise in oncology trials, with strong platform and financial position.AEMD
Emerging Growth Conference - Auditor's going concern warning and a new offering of stock and warrants highlight financial risk.AEMD
Registration filing - Operating expenses dropped 24% as Hemopurifier trials advanced in Australia and cash position improved.AEMD
Q1 2025